Inhibition of N-linked glycosylation impairs ALK phosphorylation and disrupts pro-survival signaling in neuroblastoma cell lines

BMC Cancer

Volumn 11, Issue , 2011, Pages

  Del Grosso, Federica ^a   De Mariano, Marilena ^a,b   Passoni, Lorena ^c,e   Luksch, Roberto ^c   Tonini, Gian P ^a   Longo, Luca ^a,d  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c NATIONAL CANCER INSTITUTE   (Italy)

^d Italian Neuroblastoma Foundation   (Italy)

^e UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; ARGININE; GLUTAMINE; LEUCINE; MITOGEN ACTIVATED PROTEIN KINASE 1; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PHENYLALANINE; PROTEIN KINASE B; STAT3 PROTEIN; TUNICAMYCIN; ENZYME INHIBITOR; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL DISRUPTION; CELL EXPANSION; CELL STRAIN; CELL STRAIN KELLY; CELL STRAIN LA1 5S; CELL STRAIN NB1; CELL STRAIN NB5; CELL STRAIN SH SY5Y; CELL STRAIN SU DHL1; CELL STRAIN UKF NB3; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; DOWNSTREAM PROCESSING; ENZYME DEGRADATION; HUMAN; HUMAN CELL; MUTATIONAL ANALYSIS; NEUROBLASTOMA CELL; PROTEIN EXPRESSION; PROTEIN GLYCOSYLATION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; PROTEINASE INHIBITION; SIGNAL TRANSDUCTION; DRUG EFFECT; GLYCOSYLATION; METABOLISM; NEUROBLASTOMA; PHOSPHORYLATION; PHYSIOLOGY; TUMOR CELL LINE; WESTERN BLOTTING;

BLOTTING, WESTERN; CELL LINE, TUMOR; CELL SURVIVAL; ENZYME INHIBITORS; GLYCOSYLATION; HUMANS; NEUROBLASTOMA; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; RECEPTOR PROTEIN-TYROSINE KINASES; TUNICAMYCIN;

EID: 84055178183     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-11-525     Document Type: Article

References (19)

1. Brodeur GM. Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer 2003, 3:203-216. 10.1038/nrc1014, 12612655.
2. Mossé YP, Laudenslager M, Longo L, Cole KA, Wood A, Attiyeh EF, Laquaglia MJ, Sennett R, Lynch JE, Perri P, Laureys G, Speleman F, Kim C, Hou C, Hakonarson H, Torkamani A, Schork NJ, Brodeur GM, Tonini GP, Rappaport E, Devoto M, Maris JM. Identification of ALK as a major familial neuroblastoma predisposition gene. Nature 2008, 455:930-935. 10.1038/nature07261, 2672043, 18724359.
3. Janoueix-Lerosey I, Lequin D, Brugières L, Ribeiro A, de Pontual L, Combaret V, Raynal V, Puisieux A, Schleiermacher G, Pierron G, Valteau-Couanet D, Frebourg T, Michon J, Lyonnet S, Amiel J, Delattre O. Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma. Nature 2008, 455:967-970. 10.1038/nature07398, 18923523.
4. George RE, Sanda T, Hanna M, Fröhling S, Luther W, Zhang J, Ahn Y, Zhou W, London WB, McGrady P, Xue L, Zozulya S, Gregor VE, Webb TR, Gray NS, Gilliland DG, Diller L, Greulich H, Morris SW, Meyerson M, Look AT. Activating mutations in ALK provide a therapeutic target in neuroblastoma. Nature 2008, 455:975-978. 10.1038/nature07397, 2587486, 18923525.
5. Chen Y, Takita J, Choi YL, Kato M, Ohira M, Sanada M, Wang L, Soda M, Kikuchi A, Igarashi T, Nakagawara A, Hayashi Y, Mano H, Ogawa S. Oncogenic mutations of ALK kinase in neuroblastoma. Nature 2008, 455:971-974. 10.1038/nature07399, 18923524.
6. Carén H, Abel F, Kogner P, Martinsson T. High incidence of DNA mutations and gene amplifications of the ALK gene in advanced sporadic neuroblastoma tumours. Biochem J 2008, 416:153-159. 10.1042/BJ20081834, 18990089.
7. Passoni L, Longo L, Collini P, Coluccia AM, Bozzi F, Podda M, Gregorio A, Gambini C, Garaventa A, Pistoia V, Del Grosso F, Tonini GP, Cheng M, Gambacorti-Passerini C, Anichini A, Fossati-Bellani F, Di Nicola M, Luksch R. Mutation-independent anaplastic lymphoma kinase overexpression in poor prognosis neuroblastoma patients. Cancer Res 2009, 69:7338-7346. 10.1158/0008-5472.CAN-08-4419, 19723661.
8. De Brouwer S, De Preter K, Kumps C, Zabrocki P, Porcu M, Westerhout EM, Lakeman A, Vandesompele J, Hoebeeck J, Van Maerken T, De Paepe A, Laureys G, Schulte JH, Schramm A, Van Den Broecke C, Vermeulen J, Van Roy N, Beiske K, Renard M, Noguera R, Delattre O, Janoueix-Lerosey I, Kogner P, Martinsson T, Nakagawara A, Ohira M, Caron H, Eggert A, Cools J, Versteeg R, Speleman F. Meta-analysis of neuroblastomas reveals a skewed ALK mutation spectrum in tumors with MYCN amplification. Clin Cancer Res 2010, 16(17):4353-4362. 10.1158/1078-0432.CCR-09-2660, 20719933.
9. Morris SW, Kirstein MN, Valentine MB, Dittmer KG, Shapiro DN, Saltman DL, Look AT. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science 1994, 263:1281-1284. 10.1126/science.8122112, 8122112.
10. Gupta G, Sinha S, Mitra N, Surolia A. Probing into the role of conserved N-glycosylation sites in the Tyrosinase glycoprotein family. Glycoconj J 2009, 26:691-695. 10.1007/s10719-008-9213-x, 19015978.
11. Helenius A, Aebi M. Intracellular functions of N-linked glycans. Science 2001, 291:2364-2369. 10.1126/science.291.5512.2364, 11269317.
12. Contessa JN, Bhojani MS, Freeze HH, Rehemtulla A, Lawrence TS. Inhibition of N-linked glycosylation disrupts receptor tyrosine kinase signaling in tumor cells. Cancer Res 2008, 68:3803-3809. 10.1158/0008-5472.CAN-07-6389, 18483264.
13. Abramoff MD, Magalhaes PJ, Ram SJ. Image Processing with ImageJ. Biophotonics International 2004, 11:36-42.
14. Di Paolo D, Brignole C, Pastorino F, Carosio R, Zorzoli A, Rossi M, Loi M, Pagnan G, Emionite L, Cilli M, Bruno S, Chiarle R, Allen TM, Ponzoni M, Perri P. Neuroblastoma-targeted nanoparticles entrapping siRNA specifically knockdown ALK. Mol Ther 2011, 19:1131-1140. 10.1038/mt.2011.54, 21487394.
15. Choi YL, Soda M, Yamashita Y, Ueno T, Takashima J, Nakajima T, Yatabe Y, Takeuchi K, Hamada T, Haruta H, Ishikawa Y, Kimura H, Mitsudomi T, Tanio Y, Mano H, . ALK Lung Cancer Study Group EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N Engl J Med 2010, 363:1734-1739. 10.1056/NEJMoa1007478, 20979473, ALK Lung Cancer Study Group.
16. Contessa JN, Bhojani MS, Freeze HH, Ross BD, Rehemtulla A, Lawrence TS. Molecular imaging of N-linked glycosylation suggests glycan biosynthesis is a novel target for cancer therapy. Clin Cancer Res 2010, 16:3205-3214. 10.1158/1078-0432.CCR-09-3331, 20413434.
17. Ling YH, Li T, Perez-Soler R, Haigentz M. Activation of ER stress and inhibition of EGFR N-glycosylation by tunicamycin enhances susceptibility of human non-small cell lung cancer cells to erlotinib. Cancer Chemother Pharmacol 2009, 64:539-548. 10.1007/s00280-008-0902-8, 19130057.
18. Stommel JM, Kimmelman AC, Ying H, Nabioullin R, Ponugoti AH, Wiedemeyer R, Stegh AH, Bradner JE, Ligon KL, Brennan C, Chin L, DePinho RA. Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science 2007, 318:287-290. 10.1126/science.1142946, 17872411.
19. Wang S, Pashtan I, Tsutsumi S, Xu W, Neckers L. Cancer cells harboring MET gene amplification activate alternative signaling pathways to escape MET inhibition but remain sensitive to Hsp90 inhibitors. Cell Cycle 2009, 8:2050-2056. 10.4161/cc.8.13.8861, 19502802.